Guy Montay

Sanofi (France)

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Trends

Author Order

Document Type

Co-Authors

René Bruno

Roche (France)

Armand Frydman

Université de Perpignan

A. Le Liboux

Novum Pharmaceutical Research Services (United States)

Vijay O. Bhargava

Novartis (Switzerland)

Nicole Vivier

Sanofi (France)

Y. Le Roux

Université de Rouen Normandie

Françoise Roquet

Centre d’études d’agents Pathogènes et Biotechnologies Pour la Santé

J. Gaillot

University of Oslo

Pierre Hardy

Centre Hospitalier Universitaire Sainte-Justine

Suzanne K. Swan

University of South Carolina

Cooperative Institutions

Inserm

Sorbonne Université

Université Paris Cité

Centre National de la Recherche Scientifique

Sanofi (France)

Assistance Publique – Hôpitaux de Paris

Université Claude Bernard Lyon 1

Laboratoire de Recherche Historique Rhône-Alpes

Université de Rouen Normandie

Centre Hospitalier Universitaire de Rouen

Author Statistics

Papers

Citation

H-Index

i-10 index

Research Field

A population pharmacokinetic model for docetaxel (Taxotere®): Model building and validation

Journal of Pharmacokinetics and Biopharmaceutics (1996)

René Bruno Nicole Vivier J. Vergniol Susan L. De Phillips Guy Montay

NONMEM

10.1007/bf02353487

Cite

Citations (268)

Pharmacokinetics of Quinupristin/ Dalfopristin in Patients with Severe Chronic Renal Insufficiency

Clinical Pharmacokinetics (2000)

Paul Chevalier Jacques Rey Oliver Pasquier V. Leclerc J C Baguet

Dalfopristin

Quinupristin

Tolerability

10.2165/00003088-200039010-00005

Cite

Citations (14)

Pharmacokinetic and pharmacodynamic study of suriclone imipramine interaction in man

Fundamental and Clinical Pharmacology (1994)

Perault Mc G. Chapelle S. Bouquet P. Chevalier Guy Montay

Suriclone is a novel cyclopyrrolone exhibiting anxiolytic activity. Twelve healthy Caucasian male volunteers participated in the study. A single dose of suriclone 0.4 mg, imipramine 75 mg, suriclone 0.4 mg + imipramine 75 mg, or placebo was given according to a 4 x 4 Latin-square design in order to assess the effect of drug association on pharmacokinetics and psychomotor performances. Visual analogue scale ratings, critical flicker frequency, choice visual reaction time, and Pauli, picture memory and Sternberg tests were performed before and 1.5, 6 and 9 h after drug administration. Suriclone, with the exception of the Pauli test, had no effect on psychomotor performances. The imipramine-suriclone association appeared to disturb some performances (no statistical significance), probably due to the effect of imipramine. Blood samples were collected for determination of imipramine and suriclone plasma levels respectively by high-performance liquid chromatography and radioimmunoassays. Suriclone AUC, Cmax and Tmax were not affected by imipramine, and reciprocally.

Pharmacodynamics

Flicker fusion threshold

10.1111/j.1472-8206.1994.tb00806.x

Cite

Citations (2)

Bactericidal activity and kinetics of RP 59500 in a mouse model of Staphylococcus aureus septicaemia

Journal of Antimicrobial Chemotherapy (1995)

Nadine Berthaud Guy Montay Bernard J. Conard J. F. Desnottes

Journal Article Bactericidal activity and kinetics of RP 59500 in a mouse model of Staphylococcus aureus septicaemia Get access Nadine Berthaud, Nadine Berthaud aCentre de Recherche, Rhône-Poulenc Rorer S. A., 13, quai J. Guesde94403 Vitry-sur-Seine Search for other works by this author on: Oxford Academic PubMed Google Scholar Guy Montay, Guy Montay bInstitut de Biopharmacie, Rhône-Poulenc Rorer S.A., 20 avenue R. Aron92165 Antony, France Search for other works by this author on: Oxford Academic PubMed Google Scholar Bernard J. Conard, Bernard J. Conard bInstitut de Biopharmacie, Rhône-Poulenc Rorer S.A., 20 avenue R. Aron92165 Antony, France Search for other works by this author on: Oxford Academic PubMed Google Scholar Jean-Francois Desnottes Jean-Francois Desnottes * aCentre de Recherche, Rhône-Poulenc Rorer S. A., 13, quai J. Guesde94403 Vitry-sur-Seine *Corresponding author. Phone: +33(1)-45737678; Fax: +33-(1)-45737960. Search for other works by this author on: Oxford Academic PubMed Google Scholar Journal of Antimicrobial Chemotherapy, Volume 36, Issue 2, August 1995, Pages 365–373, https://doi.org/10.1093/jac/36.2.365 Published: 01 August 1995 Article history Received: 26 July 1994 Revision received: 17 February 1995 Accepted: 20 April 1995 Published: 01 August 1995

10.1093/jac/36.2.365

Cite

Citations (14)

A population pharmacokinetic (PPK) analysis of dalfopristin/quinupristin (D/Q), a new injectable antibiotic

Clinical Pharmacology & Therapeutics (1999)

René Bruno Nicole Vivier P. Baille S ROUAULT Guy Montay

Quinupristin

Dalfopristin

Population Pharmacokinetics

10.1016/s0009-9236(99)80182-9

Cite

Citations (1)

[A method of determination of lidocaine and etidocaine in the blood by gas chromatography].

PubMed (1978)

M Vigouroux Guy Montay N’guessan B. Benoit Larry G. Duckert Florian Roquet

Source

Cite

Citations (0)

Effect of ketoconazole on the pharmacokinetics and safety of telithromycin and clarithromycin in older subjects with renal impairment

International Journal of Clinical Pharmacology and Therapeutics (2005)

Jun Yi Shi Sunny Chapel Guy Montay Pierre Hardy Jeffrey S. Barrett

The objective of this study was to determine the effect of multiple impairments in drug elimination on the pharmacokinetics and pharmacodynamics (effect on QTc interval), using clarithromycin as a comparator.Thirty-two subjects aged > or = 60 years with renal impairment who were otherwise medically stable were recruited into this parallel-group study. Following stratification according to creatinine clearance (CL(CR)), subjects were randomized to a five-day treatment with ketoconazole (400 mg once daily) alone, or a five-day treatment with ketoconazole (400 mg once daily) and telithromycin (800 mg once daily) given concomitantly or a five-day treatment with ketoconazole (400 mg once daily) and clarithromycin (500 mg twice daily) given concomitantly. Steady-state pharmacokinetics and safety, including serial electrocardiograms, were assessed.In subjects with CL(CR) 30 - 80 ml/min, the mean maximal telithromycin concentration at steady state (C(max),ss) was 3.6 mg/l and the steady state area under the plasma concentration-time curve from time zero to 24 hours (AUC(0-24 h) ss) was 33.4 mg x h/l. The mean C(max), ss and AUC(0-12 h)ss for clarithromycin were 6.2 mg/l and 56.1 mg x h/l, respectively. The increases in telithromycin C(max) ss and AUC(0-24 h) ss compared to corresponding data for healthy young subjects were 1.6- and 2.7-fold, respectively, whereas corresponding increases for clarithromycin were 2.2- and 3.3-fold, respectively. In the telithromycin plus ketoconazole group deltaQTc values were equal or < 60 ms. All QTc values were equal or < 450 ms in males and equal or < 470 ms in females.The increase in telithromycin plasma concentrations during ketoconazole-mediated inhibition of CYP3A4 in subjects aged 60 years or older with renal impairment was similar to that for clarithromycin under the same conditions. Telithromycin was well tolerated and produced no clinically significant prolongations in the QTc interval.

Telithromycin

Pharmacodynamics

10.5414/cpp43123

Cite

Citations (27)

Aprikalim: Radioimmunoassay and Pharmacokinetic Studies in Mouse, Monkey, and Dog

Journal of Pharmaceutical Sciences (1994)

Paul Chevalier Christiane Rouillard Guy Montay Armand Frydman

Beagle

Hapten

Free fraction

10.1002/jps.2600830321

Cite

Citations (6)

[Utilisation of pipemidic acid as antibiotic in patients with renal failure insufficiency. Kinetics of serum and urinary concentrations (author's transl)].

PubMed (1979)

A Meyrier O Kourilsky Guy Montay Le Verge R

Chronic pyelonephritis

Chronic renal failure

Serum concentration

Source

Cite

Citations (1)

Design of yeast-secreted albumin derivatives for human therapy: biological and antiviral properties of a serum albumin-CD4 genetic conjugate.

Proceedings of the National Academy of Sciences (1992)

P Yeh D Landais Marc Lemaître Isabelle Maury Jean-Yves Crenne

Due to its remarkably long half-life, together with its wide in vivo distribution and its lack of enzymatic or immunological functions, human serum albumin (HSA) represents an optimal carrier for therapeutic peptides/proteins aimed at interacting with cellular or molecular components of the vascular and interstitial compartments. As an example, we designed a genetically engineered HSA-CD4 hybrid aimed at specifically blocking the entry of the human immunodeficiency virus into CD4+ cells. In contrast with CD4, HSA-CD4 is correctly processed and efficiently secreted by Kluyveromyces yeasts. In addition, its CD4 moiety exhibits binding and antiviral in vitro properties similar to those of soluble CD4. Finally, the elimination half-life of HSA-CD4 in a rabbit experimental model is comparable to that of control HSA and 140-fold higher than that of soluble CD4. These results indicate that the genetic fusion of bioactive peptides to HSA is a plausible approach toward the design and recovery of secreted therapeutic HSA derivatives with appropriate pharmacokinetic properties.

Human serum albumin

Conjugate

Serum Albumin

Ex vivo

10.1073/pnas.89.5.1904

Cite

Citations (112)